Pretransplant Immediately Early-1-Specific T Cell Responses Provide Protection for CMV Infection After Kidney Transplantation

This publication has 47 references indexed in Scilit:

• ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—even in hands of ELISPOT-inexperienced investigators
  Journal of Immunotoxicology, 2009
• Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients
  American Journal of Transplantation, 2009
• High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function
  Transplant Immunology, 2009
• Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal Transplantation
  American Journal of Transplantation, 2008
• Symptomatic and Asymptomatic Viral Recrudescence in Solid-Organ Transplant Recipients and Its Relationship with the Antigen-Specific CD8 ⁺ T-Cell Response
  Journal of Virology, 2007
• Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
  Cancer Immunology, Immunotherapy, 2007
• Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects
  Journal of Experimental Medicine, 2005
• Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease
  Journal of Experimental Medicine, 2005
• A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half Dose) for Preemptive Therapy of Cytomegalovirus Infection in Transplant Recipients
  The Journal of Infectious Diseases, 2004
• SYMPTOMATIC CYTOMEGALOVIRUS INFECTION IN SEROPOSITIVE KIDNEY RECIPIENTS: REINFECTION WITH DONOR VIRUS RATHER THAN REACTIVATION OF RECIPIENT VIRUS
  The Lancet, 1988